The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
6d
Hosted on MSNGilead’s lenacapavir applications for HIV gain EMA validationGilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal.Approximately, 1 ...
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
Lenacapavir is a twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor intended to prevent HIV as pre-exposure prophylaxis (PrEP). The latest announcement follows the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results